Top Markets
Coin of the day
Handa Pharmaceuticals, Inc. Handa Pharmaceuticals, Inc.

Handa Pharmaceuticals, Inc.

6620
Peringkat dalam Saham #13384
Handa Pharmaceuticals, Inc. operates as a specialized drug company,... Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.
Harga Saham
$2.95
Kapitalisasi Pasar
$491.95M
Perubahan (1 hari)
9.94%
Perubahan (1 tahun)
8.06%
Negara
TW
Perdagangan Handa Pharmaceuticals, Inc. (6620)

Kategori

Riwayat hasil dividen untuk Handa Pharmaceuticals, Inc. (6620)
Hasil dividen (TTM) dari Handa Pharmaceuticals, Inc. (simbol saham: 6620) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk Handa Pharmaceuticals, Inc. (6620) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing